Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

NCT04362072 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
71
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer